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ABSTRACT:
TET enzymes are the epigenetic factors involved in the formation of the sixth 
DNA base 5-hydroxymethylcytosine, whose deregulation has been associated 
with tumorigenesis. In particular, TET1 acts as tumor suppressor preventing cell 
proliferation and tumor metastasis and it has frequently been found down-regulated 
in cancer. Thus, considering the importance of a tight control of TET1 expression, the 
epigenetic mechanisms involved in the transcriptional regulation of TET1 gene are 
here investigated. The involvement of poly(ADP-ribosyl)ation in the control of DNA and 
histone methylation on TET1 gene was examined. PARP activity is able to positively 
regulate TET1 expression maintaining a permissive chromatin state characterized by 
DNA hypomethylation of TET1 CpG island as well as high levels of H3K4 trimethylation. 
These epigenetic modifications were affected by PAR depletion causing TET1 down-
regulation and in turn reduced recruitment of TET1 protein on HOXA9 target gene. In 
conclusion, this work shows that PARP activity is a transcriptional regulator of TET1 
gene through the control of epigenetic events and it suggests that deregulation of 
these mechanisms could account for TET1 repression in cancer.
INTRODUCTION
Ten-Eleven translocation (TET) family 
enzymes, namely TET1, TET2 and TET3, are new 
important epigenetic regulators of gene expression 
[1]. Their epigenetic action depends on the ability 
to convert 5-methylcytosine (5mC) primarily to 
5-hydroxymethylcyosine (5hmC) and then to 
5-formylcytosine or 5-carboxylcytosine [2]. These 
sequential modifications of 5mC are initial steps in active 
DNA demethylation processes based on DNA repair 
pathways [1,3]. However, 5hmC is actually considered a 
stable epigenetic mark of DNA other than an intermediate 
of active DNA demethylation [1,4,5]. In fact, TET 
proteins modulate DNA methylation and transcription 
acting in embryonic development, stem cell function 
and differentiation [4,6]. TET1 and TET2 participate in 
the DNA demethylation during germline development 
[7] while the epigenetic reprogramming of mammalian 
zygote mainly depends on TET3 enzymatic activity [8]. 
Furthermore, TET1 and TET2 are involved in stem cell 
biology promoting transcription of pluripotency factors 
and repressing developmental regulators [9-11]. Besides 
producing 5hmC and its derivatives, TET enzymes are 
involved in epigenetic events also controlling O-linked 
β-N-acetylglucosaminylation (GlcNAcylation) and in turn 
histone H3K4 methylation [12,13]. 
The importance of TET enzymes is also 
demonstrated by the pathological consequences deriving 
from their deregulation [6]. Dysfunction of TET enzymatic 
activity can be accompanied by a decrease in 5hmC 
levels which is now considered an epigenetic hallmark 
of human cancers [14-16]. TET1 and TET2 generally 
act as tumor suppressors regulating cancer development, 
growth and invasion [17-19]. Accordingly, frequent 
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somatic mutations in TET2 gene have been identified 
in hematopoietic malignancies [20,21]. Rare genetic 
anomalies were also identified for TET1 gene [22-24] 
but down-regulation of TET1 has more frequently been 
observed during transformation [14,18,25]. However, the 
epigenetic mechanisms necessary for a tight control of 
TET1 expression are largely unknown and thus they are 
here investigated. 
Attention has been focused on poly(ADP-ribosyl)
ation (PARylation), a reversible post-translational 
modification catalysed by PARP family enzymes which 
covalently introduce ADP-ribose polymer (PAR) 
chains onto acceptor proteins [26,27]. Notably, target 
proteins can also undergo non-covalent modification 
by PARs when bringing specific PAR-binding modules 
[28-30]. Another important feature of PARylation 
is the automodification reaction according to which 
some PARP enzymes, primarily the founding member 
PARP-1 (also known as ARTD1) [31] and its highly 
homologous protein PARP-2/ARTD2, synthesize PARs 
on themselves [26,30,32]. PARP-1 has historically been 
studied for its functions in DNA damage response but 
it plays important roles in transcriptional regulation 
driving epigenetic events [30,33,34]. In fact, PARP-
1 enzyme orchestrates chromatin dynamics acting on 
histones and DNA methylation machinery [33,35,36]. 
PARP-1 loosens chromatin structure modifying core and 
linker histones [33,36] but it also modulates the catalytic 
activity of chromatin enzymes as observed for the covalent 
modification of the histone demethylases KDM5B and 
KDM4D [37,38]. Also non-covalent interaction with PARs 
can regulate enzymatic activities as demonstrated for the 
inhibition of the DNA methyltransferase Dnmt1 [39] or 
the activation of the nucleosome-remodeling ATPase 
ALC1 [40,41]. On the basis of this evidence, this paper 
investigated the involvement of PARylation in the control 
of TET1 highlighting a key contribution of PARP activity 
in the regulation of both DNA and histone methylation. 
RESULTS
DNA methylation and histone H3K4 
trimethylation control TET1 expression
Expression analysis of TET1 gene was performed 
on human T-cell acute lymphoblastic leukemia (T-ALL) 
cell lines (JURKAT, MOLT-3, SKW-3) and on cell lines 
of human breast cancer origin (MDA-MB-231, MCF7, 
T47D, MDA-MB-453). TET1 expression was detectable 
in all samples tested but transcription levels were quite 
different. SKW-3 and MDA-MB-453 showed the lowest 
TET1 expression out of T-ALL and breast cancer cell lines, 
respectively (Figure 1A). Considering the presence of a 
Figure 1: DNA hypermethylation of TET1 CpG island associates with low TET1 expression. (A) qRT-PCR analysis of TET1 
gene expression in T-ALL and breast cancer cell lines. The results are shown as means ± S.E.M. (n=3). P-value was determined by One-
way ANOVA test followed by Tukey post test (*P<0.05; **P<0.01). (B) Schematic representation of TET1 gene where TSS and CGI are 
indicated. The expanded region corresponds to the fragment amplified by PCR after endonuclease restriction for DNA methylation analysis. 
Each stick is a CpG and each circle represents the internal CpG in the 5’-CCGG-3’ tetranucleotide recognized by both MspI and HpaII. (C) 
Analysis of TET1 DNA methylation using MspI/HpaII restriction and PCR amplification performed on T-ALL and breast cancer cell lines. 
U, uncut; H, HpaII; M, MspI.
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CpG island (CGI) located close to the transcription start 
site (TSS) of TET1 gene (Figure 1B), the methylation 
state of TET1 CGI in each cell line was investigated. DNA 
was digested with the methylation-sensitive endonuclease 
HpaII followed by PCR amplification of a CGI region 
containing HpaII restriction sites. Amplification product 
was only obtained for TET1 low expressing cell lines 
(SKW-3 and MDA-MB-453) thus indicating that their 
CGI was methylated (Figure 1C). 
To gain insight into TET1 gene regulation, 
analysis was focused on two cell lines differing in 
the transcriptional activity of TET1 gene: MOLT-3 
cells (high TET1 expression) and SKW-3 cells (low 
TET1 expression). Accordingly, western blot analysis 
demonstrated that TET1 protein level in these cell lines 
was consistent with mRNA expression (Figure 2A). 
Epigenetic characterization of TET1 promoter in MOLT-
3 and SKW-3 cells was focused on DNA and histone 
methylation. MassARRAY EpiTYPER was used to assess 
DNA methylation profile of TET1 gene demonstrating 
that low TET1 expression in SKW-3 was associated 
with heavily methylated TET1 CGI (Figure 2B and C). 
However, EpiTYPER does not discriminate between 5mC 
and 5hmC [42], thus experiments with glucosyltransferase 
enzyme were performed [43]. The absence of PCR 
amplification following glucosyltransferase reaction and 
MspI restriction demonstrated that TET1 CGI in SKW-
3 cells was methylated and not hydroxymethylated 
(Supplementary Figure S1A). On the basis of these results, 
the effective involvement of DNA methylation in the 
repression of TET1 was demonstrated by treating SKW-
3 cell line with the demethylating agent 5-azacytidine 
(5-aza). In fact, after 48 hrs of treatment, demethylation 
of TET1 CGI was observed together with a dose-
dependent increase in TET1 expression (Figure 2D and E; 
Supplementary Figure S1B). 
Figure 2: DNA methylation negatively regulates TET1 transcription. (A) Western blot analysis of TET1 protein in MOLT-3 
and SKW-3 cell lines. LAMIN B1 (LMNB1) was used as loading control. (B) Schematic representation of TET1 gene where the expanded 
region is the fragment investigated by EpiTYPER assay for DNA methylation analysis. Each stick is a CpG and each circle represents CpGs 
detectable by EpiTYPER assay. (C) DNA methylation analysis of TET1 CGI performed by using EpiTYPER assay. (D) Analysis of TET1 
DNA methylation using MspI/HpaII restriction and PCR amplification performed on SKW-3 cells treated for 48 hrs with different doses of 
5-azacytidine (5-aza). U, uncut; H, HpaII; M, MspI. (E) qRT-PCR analysis of TET1 gene expression on SKW-3 cells treated for 48 hrs with 
different doses of 5-aza. The results are shown as means ± S.E.M. (n=3). P-value was determined by paired Student’s t-test (**P<0.01).
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As concerns histone methylation, the presence of 
typical active (H3K4 trimethylation) and inactive (H3K9 
trimethylation) chromatin marks was examined on TET1 
promoter. ChIP experiments demonstrated that H3K4 
trimethylation was highly enriched in MOLT-3 with 
respect to SKW-3 (Supplementary Figure S1C) while 
H3K9 trimethylation was undetectable in both cell lines 
(data not shown). These results are in agreement with the 
transcriptional state of TET1 in MOLT-3 and SKW-3.
PARylation is involved in the transcriptional 
control of TET1 gene
The potential involvement of PARylation in the 
regulation of TET1 gene was examined as PARP activity 
was shown to influence TET1 expression in germline [44] 
and it is able to control DNA and histone methylation 
[35,37,38,45,46]. 
ChIP analysis was used to investigate the presence 
of PARP-1 and its enzymatic products, PARs, on 
regulative regions of TET1 gene as promoter (fragment A), 
TSS (fragment B) and CGI (fragment C). A distal region 
was used as negative control (fragment D) (Figure 3A). 
This analysis revealed that PARP-1 and PARs were highly 
enriched in unmethylated TET1 gene in MOLT-3 cells with 
respect to methylated TET1 gene in SKW-3 (Figure 3B 
and C). Analysis of PARP-1 expression, PAR levels and 
DNA methylation profile of PARP-1 CGI indicated that 
the different localization of PARP-1/PAR on TET1 gene 
in the two cell lines was not due to general differences 
in PARP-1 expression or activity (Supplementary Figure 
S2). ChIP assay was also performed on additional cell 
lines: HEK293T, which showed high TET1 expression/
demethylated CGI, and HeLa showing low TET1 
expression/methylated CGI (Supplementary Figure S3A, 
B and C). Also in this case PARP-1 protein and PARs were 
mainly present on the TET1 gene with high expression and 
Figure 3: PARylation is involved in the transcriptional regulation of TET1 gene. (A) Schematic representation of TET1 gene 
where arrows indicate the localization of fragments analyzed by ChIP assay. Fragment A is localized in promoter region, fragment B is very 
close to TSS, fragment C is in CGI region. Fragment D is used as negative control. (B,C) Analysis of PARP-1 and PARs presence on TET1 
gene regulative regions performed by ChIP assay followed by qPCR in MOLT-3 and SKW-3 cell lines. The results are shown as percentage 
of input and are means ± S.E.M. (n=3). (D,E) qRT-PCR analysis of TET1 gene expression performed after treatment of MOLT-3 and SKW-
3 cell lines with 1μM ABT-888 and 1μM PJ-34 for 72 hrs. The results are shown as means ± S.E.M. (n=4). P-value was determined by 
paired Student’s t-test (*P<0.05; **P<0.01).
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unmethylated CGI (Supplementary Figure S3D and E). 
The effective involvement of PARylation in 
TET1 transcription was assessed using two potent 
PARP inhibitors, PJ-34 and ABT-888, at concentrations 
not affecting cell growth (Supplementary Figure S4). 
Transcriptional analysis showed that TET1 gene expression 
was significantly decreased in MOLT-3 cell after treatment 
with 1μM PJ-34 and 1μM ABT-888 indicating the 
involvement of PARP activity in the positive regulation 
of unmethylated TET1 gene (Figure 3D). Notably, no 
effect on TET1 transcription was instead observed when 
PARP inhibition was performed in SKW-3 cells (Figure 
3E) which showed low PARP-1/PARs content on TET1 
gene and methylated TET1 CGI. Confirmatory findings 
were obtained in the highly transfectable HEK293T cell 
line following overexpression of the PAR-degrading 
enzyme PARG which led to down-regulation of TET1 
gene (Supplementary Figure S5A and B). Moreover, the 
silencing of PARP-1 and/or PARP-2 also reduced TET1 
transcription (Supplementary Figure S5C and D).
PARylation controls methylation of both DNA and 
histone H3K4 on TET1 gene
The way of action of PARylation on TET1 
expression was investigated focusing on epigenetic events 
driven by PARP activity [33]. Attention was initially 
addressed to DNA methylation. Analysis of MOLT-3 
cells revealed that TET1 CGI became insensitive to HpaII 
cleavage after treatment with both PJ-34 and ABT-888 
(Figure 4B and Supplementary Figure S6A). No changes 
were instead observed in SKW-3 cells whose TET1 CGI 
was already methylated (Figure 4B). The addition of new 
methyl groups on TET1 CGI of MOLT-3 cells in absence 
of PARs was then evidenced by bisulfite sequencing 
(Figure 4C). Glucosyltransferase-based experiments 
finally demonstrated that 5mC and not 5hmC was 
introduced onto TET1 CGI after PARP inhibition (Figure 
4D).
Besides DNA methylation, PARP activity is able to 
control histone H3K4 and H3K9 trimethylation [37,38]. 
Considering the absence of H3K9 trimethylation in 
both MOLT-3 and SKW-3, the effect of PAR depletion 
was assessed on H3K4 methylation states. MOLT-3 
cells were treated with PJ-34 and the efficacy of PARP 
inhibition was demonstrated by ChIP assay with anti-PAR 
antibody (Supplementary Figure S6B). PAR removal 
was associated with a consistent decrease in H3K4 
trimethylation occupancy, while no particular change was 
observed in H3K4 mono- and dimethylation (Figure 5). 
The recruitment of the RNA polymerase II (RNA POL 
II) was also investigated demonstrating less loading of 
this enzyme at the TSS of TET1 gene in PARP-inhibited 
MOLT-3 cells (Figure 5). Notably, PJ-34 had no effect 
regarding H3K4 methylation states on TET1 gene in 
Figure 4: PARylation regulates DNA methylation patterns of TET1 CpG island. (A) Schematic representation of TET1 gene 
where fragments BC (arrows) and A (arrowheads), amplified by PCR after endonuclease restriction for DNA methylation analysis, are 
indicated. Fragment BC contains recognition sites for MspI/HpaII which are not present in fragment A. The expanded region corresponds to 
the fragment analyzed by bisulfite sequencing where each stick is a CpG dinucleotide. (B) Analysis of TET1 DNA methylation using MspI/
HpaII restriction and PCR amplification performed on MOLT-3 and SKW-3 treated for 72 hrs with 1μM PJ-34 or 1μM ABT-888. Fragment 
A was used as loading control. (C) Analysis of TET1 DNA methylation by bisulfite sequencing performed on MOLT-3 treated for 72 hrs 
with 1μM PJ-34 or 1μM ABT-888. Each clone is represented by a row, and the CpG dinucleotide being investigated is arranged in columns. 
White and black circles represent unmethylated and methylated/modified cytosines, respectively. (D) Analysis of DNA hydroxymethylation 
of TET1 CGI performed using glucosyltransferase reaction and MspI restriction followed by PCR amplification. Fragment A was used as 
loading control. Analysis was performed on MOLT-3 treated for 72 hrs with 1μM PJ-34 or 1μM ABT-888. 
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SKW-3 cells (Supplementary Figure S7). 
PARylation regulates TET1 protein level and 
recruitment on HOXA9 target gene
Considering that PARP inhibition affects the 
transcription of TET1 gene, TET1 protein level was 
assessed in MOLT-3 cells after PJ-34 and ABT-888 
treatment. Western blots and related densitometric 
analyses of total, nuclear and cytosolic fractions showed a 
slight decrease in TET1 protein level after PARP inhibition 
consistently with mRNA down-regulation (Figure 6A, B 
and Supplementary Figure S8). A possible effect of PARP 
inhibition on TET1 protein functions was assessed by 
ChIP assay on HOXA9 gene, a known target of TET1 
enzyme [19]. Notably, the recruitment of TET1 on HOXA9 
target region was affected after depletion of PARs (Figure 
6C). 
DISCUSSION
TET1 protein acts as tumor suppressor gene 
regulating critical pathways involved in cell proliferation 
and tumor metastasis [19,47]. Despite rare genetic 
mutations of TET1 gene having been identified [22-
24], association between TET1 down-regulation and 
5hmC decrease has more frequently been observed in 
tumorigenesis [14,18,25]. The cause of TET1 down-
regulation in tumors is largely unknown, thus potential 
epigenetic mechanisms underlying TET1 transcriptional 
deregulation in cancer cells have been here investigated. 
Analysis was initially addressed to DNA 
methylation, a well-known epigenetic modification able 
to repress expression of tumor suppressor genes [48]. 
TET1 expression was shown to be negatively regulated by 
methylation of the CGI located at the 5’ of the gene [19]. 
Analyses were here extended to several cancer cell lines 
and indicated that hypermethylation of TET1 CGI was 
only able to reduce TET1 transcription without causing 
complete silencing. Accordingly, no paper has reported a 
complete repression of TET1 in cancer but only its down-
regulation [14,18,25]. 
The study of TET1 regulation continued comparing 
cell lines with different levels of TET1 expression to 
characterize chromatin environment associated with 
Figure 5: PARylation controls histone H3K4 trimethylation and RNA POL II recruitment on TET1 gene. ChIP assay 
followed by qPCR performed on TET1 regulative regions in MOLT-3 cells treated for 72 hrs with 1μM PJ-34. Localization of analyzed 
fragments is shown in figure 3A. Antibodies against mono-, di-, trimethyl-histone H3K4 and RNA POL II were used. The results are shown 
as percentage of input and are means ± S.E.M. (n=3). P-value was determined by paired Student’s t-test (*P<0.05).
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TET1 transcriptional state. MOLT-3 and SKW-3 were 
selected as model cell lines with high and low TET1 
expression, respectively. High-throughput quantitative 
DNA methylation analysis performed by MassARRAY 
EpiTYPER showed that TET1 CGI was heavily methylated 
in SKW-3 cells with respect to MOLT-3. However, 
EpiTYPER is a bisulfite-based technology and thus it does 
not discriminate between 5mC and 5hmC [42]. Therefore, 
locus-specific analysis of DNA hydroxymethylation was 
performed demonstrating that the TET1 CGI of SKW-3 
cells was methylated and not hydroxymethylated. All in 
all, these results indicated that residual TET1 expression in 
SKW-3 cells is not dependent on 5hmC and confirmed that 
DNA methylation of TET1 CGI is able to reduce TET1 
gene expression. 
In agreement with TET1 transcriptional state, 
analysis of histone methylation evidenced higher 
enrichment of the active transcription mark H3K4 
trimethylation in MOLT-3 with respect to SKW-3, 
while no signal for H3K9 trimethylation was detected. 
Therefore, the presence in SKW-3 of H3K4 trimethylation, 
which was demonstrated to permit active transcription of 
genes marked by DNA methylation [49], and the absence 
of the repressive chromatin mark H3K9 trimethylation 
finally clarified why TET1 is still expressed despite the 
methylation of its CGI.
Considering that a connection between PARylation 
and TET1 transcription was suggested [44], the molecular 
mechanism(s) underling this regulation was investigated. 
Attention was focused on the ability of PARylation to 
regulate transcription orchestrating epigenetic events. 
In fact, PARP activity was shown to protect CpGs from 
aberrant DNA methylation [50-53] and, apart from 
directly modifying histone tails [54], PARylation regulates 
chromatin structure impairing the activity of histone 
demethylases [37,38].
Figure 6: TET1 protein level and its recruitment on HOXA9 target gene are affected by PARP inhibition. (A) Western 
blot analysis performed on total protein lysates of MOLT-3 cells treated for 72 hrs with 1μM PJ-34 or 1μM ABT-888. LAMIN B1 (LMNB1) 
was used as loading control. (B) Western blot analysis of nuclear and cytosolic fractions obtained from MOLT-3 cells treated for 72 hrs 
with 1μM PJ-34 or 1μM ABT-888. LMNB1 and αTUBULIN (αTUB) were used as loading controls. (C) Schematic representation of TET1 
target gene HOXA9 where localization of primer A and B used in ChIP analysis is shown. ChIP assay followed by qPCR was performed 
using anti-TET1 antibody in MOLT-3 cells treated for 72 hrs with 1μM PJ-34. Fragment B is a known target region of TET1 protein while 
fragment A is a negative control. The results are shown as percentage of input and are means ± S.E.M. (n=3). P-value was determined by 
paired Student’s t-test (*P<0.05).
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The action of PARylation was initially assessed 
analysing the presence of PARP-1 and PARs on regulative 
regions of TET1 gene. ChIP experiments demonstrated 
that PARP-1 and PARs were mainly enriched in MOLT-
3 where TET1 gene is highly transcribed and its CGI is 
unmethylated with respect to SKW-3. These observations 
and the absence of differences in PARP-1 expression and 
activity in both cell lines indicated that the low amount 
of PARs on TET1 in SKW-3 is not dependent on global 
dysfunction of PARylation. This suggests that possible 
cofactors of PARP-1 may account for a specific regulation 
of PARP activity on TET1 gene [36,55,56]. More 
specifically, interacting partners of PARP-1 responsible 
for its recruitment and/or activation on TET1 gene may 
be deregulated in specific tumor cell lines thus affecting 
PARP-1 positive regulation of TET1 transcription.
Although standard ChIP protocol was demonstrated 
to induce PARP activity [57], in ChIP experiments here 
reported, PAR levels were mainly observed on TET1 
unmethylated CGI suggesting, however, that an effective 
difference in PARP-1 presence and/or PAR formation 
exists in cell lines with opposite TET1 transcription level.
The importance of PARP activity in the regulation of 
TET1 was demonstrated by both molecular and chemical 
approaches. Overexpression of PARG as well as silencing 
of PARP-1 and PARP-2 led to TET1 down-regulation. 
Notably, the silencing of only PARP-1 or only PARP-2 
had the same effect on TET1 regulation of the combined 
silencing of both  proteins. This result seems to suggest 
that PARP-1 and PARP-2 have a cooperative role in TET1 
regulation rather than a compensatory one. Chemical 
inhibition of PARylation was performed by treatment 
with two potent competitive PARP inhibitors, PJ-34 and 
ABT-888. TET1 gene expression was reduced after PARP 
inhibition only in MOLT-3 cells while TET1 in SKW-3 
cells was not affected. 
Notably, combination of several methods permitted 
the demonstration that TET1 down-regulation in MOLT-3 
cells after PAR depletion was associated with anomalous 
methyl groups onto TET1 CGI. Such a results is likely to 
depend on the inhibitory role played by PARs on DNA 
methyltransferase activity [39] for the maintenance of 
CpG methylation-free states [33,35].
In addition to the introduction of some methyl 
groups on TET1 CGI in MOLT-3 cells, PARP inhibitor 
treatment caused the specific reduction of H3K4 
trimethylation and less recruitment of RNA POL II 
on TET1 gene. All in all, these results, which are in 
agreement with the observed down-regulation of TET1 
in PAR-depleted MOLT-3, confirm the involvement of 
PARs in the inhibition of H3K4 demethylase activity and 
in the loading of mRNA transcription machinery [30,37]. 
Notably, the absence of changes after PARP inhibition on 
H3K4 methylation state in SKW-3 cells, which showed 
very low PAR content on hypermethylated TET1 gene, 
further indicates a positive role played by PARylation in 
the regulation of TET1 expression. 
The effects of PARP inhibition on TET1 
transcription were associated with a reduction of TET1 
protein levels. In particular, this reduction was observed 
in both nuclear and cytosolic compartments. Molecular 
consequences occurring after PARP inhibition were 
investigated analysing TET1 enrichment on a known 
target gene as the tumor suppressor HOXA9 [19]. 
Notably, reduced recruitment of TET1 on HOXA9 gene 
was evidenced in absence of PARylation. This result could 
depend on the reduced TET1 protein level even though a 
specific recruitment of TET1 mediated by PARs has also 
been suggested [58] and cannot be excluded. 
In conclusion, these results highlight for the first 
time that PARylation can orchestrate epigenetic events 
on a single locus combining its control on both DNA 
and histone H3K4 methylation (Figure 7). Notably, 
this complex regulative network mediates a tight 
transcriptional control of the new epigenetic factor TET1 
in somatic cells. Therefore, PARP deregulation could be 
responsible for aberrant TET1 down-regulation in cancer, 
as also observed for p16(INK4a), p19ARF and p53 tumor 
suppressor genes [59-62] .
MATERIAL AND METHODS
Cell cultures and treatment
Human T-cell acute lymphoblastic leukemia cell 
lines (JURKAT, MOLT-3, SKW-3) were cultured in 
high glucose RPMI (Sigma-Aldrich) containing 10% 
FBS (Sigma-Aldrich). Breast cancer cell lines (MDA-
MB-231, MCF7, T47D, MDA-MB-453), HEK293T and 
HeLa cells were grown in high glucose DMEM (Sigma-
Aldrich) containing 10% FBS (Sigma-Aldrich). All culture 
solutions were supplemented with 2 mM L-glutamine 
(Sigma-Aldrich) and 50 U/ml Penicillin–Streptomycin 
(Sigma-Aldrich). Treatments of cells were performed 
replacing medium every 24 hrs with the indicated 
inhibitors PJ-34 (Sigma-Aldrich, final concentration 
1 μM and 5 μM), ABT-888 (Enzo Life Sciences, final 
concentration 1 μM and 5 μM) and 5-azacytidine (Sigma-
Aldrich, final concentrations 0.5; 1; 2 μM).
Transfection of HEK293T cells
HEK293T cells were transfected with 
Lipofectamine 2000 reagent (Life Technologies) adopting 
the manufacturer’s protocol. For PARG overexpression, 
empty vector PCS2 (CTRL) and pCS2-Myc-PARG 
(MYC–PARG) construct (51) were used. For silencing 
experiments, cells were transfected with siGENOME 
SMARTpool PARP-1 and PARP-2 siRNA and siGENOME 
Non-Targeting siRNA (Thermo Scientific, Dharmacon) at 
Oncotarget10364www.impactjournals.com/oncotarget
a final concentration of 50 nM.
RNA extraction and quantitative RT-PCR
Total RNA was isolated from cells by using 
RNeasy mini kit (Qiagen) following the manufacturer’s 
instructions. DNA contamination was eliminated by 
RNase-free DNase (Qiagen) treatment. RNA concentration 
and quality were evaluated by spectrophotometer analysis 
and agarose gel electrophoresis. Total RNA was subjected 
to reverse transcription using SuperScript VILO cDNA 
Synthesis Kit (Life Technologies). Transcriptional analysis 
was performed by quantitative RT-PCR (qRT-PCR) using 
iCycler IQ detection system (Bio-Rad). For quantitative 
PCR reactions, Taqman Gene Expression Assays (reported 
in Supplementary Methods) and EXPRESS qPCR 
Supermix Universal (Life Technologies) were used. 
Measurement of gene expression was performed using 
the comparative cycle threshold method. For an accurate 
expression analysis, geometric mean of two reference gene 
expressions was used for normalization. Housekeeping 
genes used were β-glucuronidase (GUSB) and β-Actin 
(ACTB).
Antibodies
The following monoclonal antibodies were used: 
PARP-1 (clone C2-10; Enzo Life Sciences), PARP-2 
(Enzo Life Sciences), PAR (clone 10HA; Trevigen), TET1 
(Genetex), Myc (9E10 clone, hybridoma-conditioned 
medium), αTUB (Sigma-Aldrich). The following 
polyclonal antibodies were used: LMNB1 (Abcam), 
PARP-1 (Enzo Life Sciences), TET1 (Millipore), PAR 
(Trevigen), RNA POL II (Santa Cruz Biotech.), H3K4me1 
(Millipore), H3K4me2 (Millipore), H3K4me3 (Millipore).
Western blot analysis
Total cell lysates were prepared in RIPA buffer (50 
mM Tris-HCl at pH 7.4, 150 mM NaCl, 1% NP-40, 0.5% 
sodium deoxycholate, 0.1% SDS and 1 mM EDTA) and 
normalized for protein concentration. Cytosolic fractions 
were obtained recovering supernatant after centrifugation 
of cells previously incubated (15 min in ice) in isolation 
buffer (10 mM Tris-HCl at pH 7.8, 4 mM MgCl2, 1 mM 
EDTA, 0.5 mM DTT, 1% Triton X-100, 0.25 M Sucrose). 
Pelleted nuclei were washed once in isolation buffer 
without Triton X-100, centrifuged and lysated in RIPA 
buffer. Each buffer was supplemented with protease 
inhibitor cocktail (complete EDTA-free, Roche Applied 
Science). Protein extracts were resolved by SDS-PAGE, 
transferred onto Hybond-ECL nitrocellulose membranes 
Figure 7: Model illustrating the way of action of PARylation in the control of TET1 transcription. PARylation of 
PARP-1 or other hypothetical target proteins is able to preserve the unmethylated state of TET1 CGI as well as the presence of histone 
H3K4 trimethylation which are required for high TET1 transcription. Following deregulation of PARP activity, TET1 CGI undergoes 
hypermethylation and H3K4 trimethylation levels decrease causing TET1 gene down-regulation.
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(Amersham Biosciences) and probed with the indicated 
antibodies. Densitometric analysis was performed using 
Quantity One software.
ChIP assay
ChIP analysis was performed as previously 
described [51] with the following modifications for cells 
grown in suspension culture. Cells were cross-linked 
using 1% formaldehyde in complete medium with gentle 
shaking on a rotary shaker for 10 min. To quench cross-
linking reaction, glycine was added to a final concentration 
of 0.125 M and cells were  incubated on rotary shaker for 
5 min. After centrifugation and two PBS washes, 1×106 
cross-linked cells were pelleted and then used for each 
immunoprecipitation condition.
Genomic DNA isolation and analysis of DNA 
methylation by methylation-specific digestion 
combined with PCR or bisulfite modification 
sequencing
Genomic DNA was isolated from cells by using 
the DNeasy Blood and Tissue Kit (Qiagen) following 
the manufacturer’s instructions. For detection of TET1 
CpG island methylation, genomic DNA was subjected to 
digestion with the methylation-sensitive enzyme HpaII 
(New England Bioloabs) and the methylation-insensitive 
enzyme MspI (New England Bioloabs) for 16 hrs at 
37°C. Products from digestion were diluted and used as 
template for PCR reactions performed by using 5 PRIME 
MasterMix (5 PRIME) with specific primers (reported 
in Supplementary Methods). For bisulfite sequencing 
assay, genomic DNA was converted by using EZ DNA 
Methylation Kit (Zymo research). Amplification of the 
region of interest in TET1 CpG island was performed 
using 5 PRIME MasterMix (5 PRIME) and a specific 
primer pair (reported in Supplementary Methods). 
Fragment cloning was performed using TOPO TA-cloning 
vector (Life Technologies) and individual inserts from 
randomly selected clones were sequenced. 
EpiTYPER assay for quantitative DNA 
methylation analysis 
The EpiTYPER assay (Sequenom) was used to 
quantitatively analyze the DNA methylation state of 
PARP-1 and TET1 CGIs. 1 μg of DNA was bisulfite-
converted using the EZ-96 DNA Methylation Kit (Zymo 
Research) with the following modifications: incubation 
in CT buffer was performed for 21 cycles of 15 min at 
55°C and 30 sec at 95°C and elution of bisulfite-treated 
DNA was performed in 100 μl of water. PCR was 
performed on 10 ng of bisulfite-treated DNA using specific 
primers (reported in Supplementary Methods). The two 
TET1 amplicons mapped in regions chr10:70,320,085-
70,320,271 and chr10:70,320,251-70,320,466 respectively, 
while PARP-1 amplicon mapped in chr1:226,595,508-
226,596,006 region. After data cleaning, it was possible to 
measure the methylation state of 27 and 31 CpGs in TET1 
and PARP-1 CGIs respectively.
CpG-specific analysis of DNA hydroxymethylation 
Site-specific analysis of 5hmC was performed 
through glucosylation and digestion of genomic DNA 
with MspI (New England Bioloabs). Briefly, DNA was 
treated with 5hmC glucosyltransferase (Zymo research) 
for 16 hrs at 30°C and then subjected to MspI restriction. 
After enzymatic digestion, PCR reaction was performed 
by using 5 PRIME MasterMix (5 PRIME) and specific 
primer pairs (reported in Supplementary Methods).
Statistical Analysis
Statistical tests used and the number of replicates 
(n) performed are reported in figure legends. Data were 
considered to be statistically significant if *P<0.05 and 
**P<0.01.
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